Advanced Search
Article Contents
ABOUT THIS ARTICLE
The Innovation Medicine > 2026 Vol. 4 > No. 2 > 100213
Next Article Previous Article
NEWS & BUZZ   Open Access     Cite

Sandwich-model perioperative therapy ushers in a new era of chronic disease management in hepatocellular carcinoma

  • 1.

    Department of Hepatic Surgery, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China

More Information
  • Corresponding author: zning818@163.com
  • Received Date:  December 11, 2025
    Accepted Date:  April 15, 2026
    Published Online:  April 16, 2026
The Innovation Medicine  4(2),  https://doi.org/10.59717/j.xinn-med.2026.100213  |  Cite this article
    • FullText(HTML)
  • 加载中
    • REFERENCES
  • [1] Du X., Lu X. and Cao X. (2023). Gantt chart for updated OS and PFS after cancer targeted therapy. Innov. Med. 1:100008. DOI:10.59717/j.xinn-med.2023.100008

    View in Article CrossRef Google Scholar

    [2] Chan S.L., Sun H.C., Xu Y., et al. (2025). The Lancet Commission on addressing the global hepatocellular carcinoma burden: Comprehensive strategies from prevention to treatment. Lancet 406:731−778. DOI:10.1016/S0140-6736(25)01042-6

    View in Article CrossRef Google Scholar

    [3] Qin S., Chen M., Cheng A.L., et al. (2023). Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): A randomised, open-label, multicentre, phase 3 trial. Lancet 402:1835−1847. DOI:10.1016/S0140-6736(23)01796-8

    View in Article CrossRef Google Scholar

    [4] Yopp A., Kudo M., Chen M., et al. (2024). LBA39 Updated efficacy and safety data from IMbrave050: Phase III study of adjuvant atezolizumab (atezo) + bevacizumab (bev) vs active surveillance in patients (pts) with resected or ablated high-risk hepatocellular carcinoma (HCC). Ann. Oncol. 35:S1230. DOI:10.1016/j.annonc.2024.08.2279

    View in Article CrossRef Google Scholar

    [5] Wang Z., Fan J., Zhou S., et al. (2025). Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): A randomised phase 2/3 trial. Lancet 406:2089−2099. DOI:10.1016/S0140-6736(25)01720-9

    View in Article CrossRef Google Scholar

    • Cited by

  • Cite this article:

    Wang Y. and Zhang N. (2026). Sandwich-model perioperative therapy ushers in a new era of chronic disease management in hepatocellular carcinoma. The Innovation Medicine 4:100213. https://doi.org/10.59717/j.xinn-med.2026.100213
    Wang Y. and Zhang N. (2026). Sandwich-model perioperative therapy ushers in a new era of chronic disease management in hepatocellular carcinoma. The Innovation Medicine 4:100213. https://doi.org/10.59717/j.xinn-med.2026.100213

Welcome!

To request copyright permission to republish or share portions of our works, please visit Copyright Clearance Center's (CCC) Marketplace website at marketplace.copyright.com.

PDF
Figures(1)    

Share

  • Share the QR code with wechat scanning code to friends and circle of friends.

Article Metrics

Article views(1271) PDF downloads(325)

Relative Articles

Cited by

Catalog

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return

    {{newsColumn.name}}

    {{newsColumn.name}}

    Stay connected

    {{newsColumn.name}}

    Website copyright © Innovation Press. Published articles are licensed under CC BY with copyright retained by the authors.